Welcome to LookChem.com Sign In|Join Free

CAS

  • or

197369-14-5

Post Buying Request

197369-14-5 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

197369-14-5 Usage

Uses

Reagent used to prepare pharmaceutically active Benzodioxole derivatives.

Check Digit Verification of cas no

The CAS Registry Mumber 197369-14-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,9,7,3,6 and 9 respectively; the second part has 2 digits, 1 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 197369-14:
(8*1)+(7*9)+(6*7)+(5*3)+(4*6)+(3*9)+(2*1)+(1*4)=185
185 % 10 = 5
So 197369-14-5 is a valid CAS Registry Number.

197369-14-5Relevant articles and documents

SUBSTITUTED 2,3-BENZODIAZEPIN-4-ONES AND THE USE THEREOF

-

Page 11; 17, (2010/02/06)

The invention relates to substituted 2,3-benzodiazepin-4-ones which are antagonists or positive modulators of AMPA receptors, and the use thereof for treating, preventing or ameliorating neuronal loss associated with stroke, global and focal ischemia, CNS

Synthesis and cytotoxic activity of 1,3-benzodioxole derivatives. Note II

Micale, Nicola,Zappala, Maria,Grasso, Silvana

, p. 351 - 355 (2007/10/03)

A series of 1,3-benzodioxoles (2-12) were synthesized and evaluated for their in vitro ability to inhibit the growth of three human tumor cell lines. No cytotoxic effects were noticed with any of the test compounds at a concentration of 10-4 M.

SUBSTITUTED 2,3-BENZODIAZEPIN-4-ONES AND THE USE THEREOF

-

, (2008/06/13)

The invention relates to substituted 2,3-benzodiazepin-4-ones which are antagonists or positive modulators of AMPA receptors, and the use thereof for treating, preventing or ameliorating neuronal loss associated with stroke, global and focal ischemia, CNS trauma, hypoglycemia and surgery, as well as treating or ameliorating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease and Down's syndrome, treating, preventing or ameliorating the adverse consequences of the overstimulation of the excitatory amino acids, treating or ameliorating anxiety, psychosis, convulsions, chronic pain, glaucoma, CMV retinitis, urinary incontinence, muscular spasm and inducing anesthesia, as well as for treating or ameliorating the adverse consequences of excitatory amino acid deficiency such as schizophrenia, Alzheimer's disease and malnutrition and neural maldevelopment, and as cognition enhancers. The invention also is directed to the process for the preparation of the substituted 2,3-benzodiazepin-4-ones.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 197369-14-5